Abstract Details Title The effect of oral Steriods in Chronic Demyelinating Polyneuropathy associated with Diabetes Mellitus Topic Autoimmune Neurology Presentation(s) P5 - Poster Session 5 (5:30 PM-6:30 PM) Poster/Presentation Number 15-077 Objective To study the effect of oral steroid on chronic inflammatory demyelinating polyneuropathy associated with diabetes mellitus. Background The standard treatment of diabetic chronic inflammatory demyelinating polyneuropathy (DM-CIDP) is intravenous Immunoglobulin (IV-IG). Except for few case reports the effectiveness of much cheaper oral steroids has not been studied till now. Design/Methods The study is a single blinded randomised control trial. Diabetic patients fulfilling diagnostic criteria of idiopathic chronic inflammatory demyelinating polyneuropathy were taken. Study group received oral prednisolone at the dose of 1mg per/kg body weight to be tapered over 4 weeks for a total duration of 6 weeks and control Group continued the same treatment without any modification. The condition of the patient was accessed weekly using Neuropathy impairment scale lower limb (NIS-LL) and Visual analogue scale (VAS) and comparison was done before the treatment get started and at the end of the study period. Results Twenty patients were enrolled with 10 patients in each arm. There was significant improvement (>4 point decrease in NIS score) in 9 out of 10 patients in the study group at the end of 6 weeks. Overall, there was an improvement of 10.20±7.87 NIS Score in the steroid group, whereas controlled group showed no improvement or worsening of symptoms (P value <0.001). Significant improvement in pain was also seen in the treatment group during VAS scoring with a mean improvement of 1.70±0.95 whereas the control group showed no improvement 0.10±0.32 (P value <0.001). No significant side effect was detected except for fever due to urinary tract infection in one patient in the study group. Conclusions Oral steroids when taken for short term under regular follow are effective in reducing symptoms of Diabetic chronic inflammatory demyelinating neuropathy without causing significant glycemic or other side effects. Authors/Disclosures Thangjam S. Singh, MD, MBBS (Government of India) PRESENTER No disclosure on file